How long does it take to take Cabergoline to achieve the best results?

Cabergoline is a first-line drug for hyperprolactinemia (HPRL), and its onset time and length of treatment are common concerns among patients. Generally speaking, cabergoline can significantly reduce serum prolactin levels within a few weeks of starting treatment, and most patients can see improvements in hormonal indicators within 2 to 4 weeks, accompanied by relief of clinical symptoms, such as reduction of galactorrhea, recovery of menstrual cycles, and improvement of fertility. Due to its long half-life, the stabilizing effect gradually appears. Usually, after three months of continuous treatment, the patient's hormone levels can stabilize. This period is considered a critical window period for initial efficacy observation.

However, achieving optimal results often requires longer periods of continued treatment. Clinical practice shows that after taking medication regularly for 6 to 12 months, patients not only achieve significant control in hormone levels, but also see a significant increase in tumor shrinkage or improvement in related symptoms. Some patients can even achieve long-term remission after more than a year of maintenance treatment. Therefore, the best results are often not achieved overnight, but a step-by-step process. Regarding the effectiveness of long-term use, there are still limited research data for more than 24 months of treatment, but existing data show that a considerable number of patients still maintain the efficacy after more than two years of continuous treatment, and the side effects are generally controllable.

It should be emphasized that efficacy evaluation cannot rely solely on hormone levels, but also needs to be combined with clinical manifestations and imaging follow-up. For example, for patients with pituitary prolactinoma, tumor shrinkage is also an important indicator of efficacy. Some patients may meet the conditions for drug discontinuation after one to two years of drug treatment, but the risk of recurrence after drug discontinuation varies between individuals and requires continued follow-up.

Reference materials:https://www.drugs.com/mtm/cabergoline.html